Yan Leyfman, Co-founder and Executive Director of MedNews Week, shared a post on LinkedIn about a recent paper by Armin Ghobadi et al. published in The Lancet:

“Fate Therapeutics Inc.’s (iPSC)-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy with 3 antitumour modalities: a CD19 CAR; a high-affinity, non-cleavable CD16 Fc receptor; and interleukin-15-interleukin-15 receptor fusion demonstrated efficacy in 86 patients after 4 prior lines of therapy with B-cell lymphoma.

Low grade CRS and no neurotoxicity observed.”

“Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial”

Authors: Armin Ghobadi, Veronika Bachanova, Krish Patel, Rebecca Elstrom, Paolo Strati et al.

Yan Leyfman: iPSC-derived CAR-NK cell therapy with three antitumor modalities

Yan Leyfman MD, is the Co-founder and executive director of MedNews Week. He is also the Medical correspondent at OncLive. He is the Executive Committee Member at Music Beats Cancer.

He is a Clinical Researcher at Icahn School of Medicine at Mount Sinai. His research interests include oncology, Immunooncology, Cellular Therapy, and Immunotherapy.